危重急性呼吸衰竭患儿咪达唑仑剂量优化:群体药代动力学-药物基因组学研究
该前瞻性药代动力学-药物基因组学观察研究纳入美国13个PICU中因急性呼吸衰竭接受机械通气、体重≥7 kg且接受吗啡和/或咪达唑仑持续输注的患儿,连续采血测定咪达唑仑及其代谢物浓度,并用全基因组SNP芯片进行基因分型,建立非线性混合效应模型。结果显示体重、年龄、肝肾功能及UGT2B7 rs62298861多态性是咪达唑仑药代动力学参数的相关预测因子;估计咪达唑仑清除率为0.61 L/min/70kg,达到50%完全成熟咪达唑仑清除率和1'-羟基咪达唑仑/4'-羟基咪达唑仑清除率的时间分别为矫正胎龄后1.0年和0.97年。最终模型提示丙氨酸转氨酶升高时咪达唑仑清除率下降,肾功能不全时葡萄糖醛酸代谢物清除率降低;UGT2B7基因rs62298861和rs28365062呈高度连锁不平衡,次要等位基因与白种人1'-羟基咪达唑仑代谢物清除率较高相关,杂合子和纯合子次要等位基因携带者的清除率分别较主要等位基因纯合子预期增加10%和20%。作者结论认为该研究为未来实施基于个体的镇静方法提供了基础。
要点
- 在急性呼吸衰竭机械通气患儿中,体重、年龄、肝肾功能及UGT2B7 rs62298861多态性是咪达唑仑药代动力学参数的相关预测因子。
- 估计咪达唑仑清除率为0.61 L/min/70kg;达到50%完全成熟咪达唑仑清除率和1'-羟基咪达唑仑/4'-羟基咪达唑仑清除率的时间分别为矫正胎龄后1.0年和0.97年。
- 最终模型提示丙氨酸转氨酶升高时咪达唑仑清除率下降,肾功能不全时葡萄糖醛酸代谢物清除率降低。
- UGT2B7 rs62298861和rs28365062呈高度连锁不平衡,次要等位基因与白种人1'-羟基咪达唑仑代谢物清除率较高相关。
- 在药代动力学-药物基因组学模型中,杂合子和纯合子次要等位基因携带者的清除率分别较主要等位基因纯合子预期增加10%和20%。
适用人群与场景
- 美国13个PICU中因急性呼吸衰竭接受机械通气的患儿,体重≥7 kg,接受吗啡和/或咪达唑仑持续输注。
研究设计与关键结果
- 前瞻性药代动力学-药物基因组学观察研究,纳入美国13个PICU中因急性呼吸衰竭机械通气、体重≥7 kg且接受吗啡和/或咪达唑仑持续输注的患儿,连续采血测定咪达唑仑及其代谢物浓度,单次采血进行基因组评估。
- 采用Illumina HumanOmniExpress全基因组SNP芯片进行基因分型,非线性混合效应模型建立药代动力学-药物基因组学模型。
- 体重、年龄、肝肾功能及UGT2B7 rs62298861多态性是咪达唑仑药代动力学变量的相关预测因子。
- 估计咪达唑仑清除率为0.61 L/min/70kg;达到50%完全成熟咪达唑仑清除率和1'-羟基咪达唑仑/4'-羟基咪达唑仑清除率的时间分别为矫正胎龄后1.0年和0.97年。
- 最终模型提示丙氨酸转氨酶升高时咪达唑仑清除率下降,肾功能不全时葡萄糖醛酸代谢物清除率降低。
- UGT2B7基因rs62298861和rs28365062呈高度连锁不平衡,次要等位基因与白种人1'-羟基咪达唑仑代谢物清除率较高相关。
- 在药代动力学-药物基因组学模型中,杂合子和纯合子次要等位基因携带者的清除率分别较主要等位基因纯合子预期增加10%和20%。
证据类型、等级与局限
- 证据类型:前瞻性药代动力学-药物基因组学观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,该研究利用非遗传和遗传因素对急性呼吸衰竭机械通气患儿咪达唑仑药代动力学的影响,为未来实施基于个体的镇静方法提供了基础。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop a pharmacokinetic-pharmacogenomic population model of midazolam in critically ill children with primary respiratory failure.
DESIGN: Prospective pharmacokinetic-pharmacogenomic observational study.
SETTING: Thirteen PICUs across the United States.
PATIENTS: Pediatric subjects mechanically ventilated for acute respiratory failure, weight greater than or equal to 7 kg, receiving morphine and/or midazolam continuous infusions.
INTERVENTIONS: Serial blood sampling for drug quantification and a single blood collection for genomic evaluation.
MEASUREMENTS AND MAIN RESULTS: Concentrations of midazolam, the 1' (1`-hydroxymidazolam metabolite) and 4' (4`-hydroxymidazolam metabolite) hydroxyl, and the 1' and 4' glucuronide metabolites were measured. Subjects were genotyped using the Illumina HumanOmniExpress genome-wide single nucleotide polymorphism chip. Nonlinear mixed effects modeling was performed to develop the pharmacokinetic-pharmacogenomic model. Body weight, age, hepatic and renal functions, and the UGT2B7 rs62298861 polymorphism are relevant predictors of midazolam pharmacokinetic variables. The estimated midazolam clearance was 0.61 L/min/70kg. Time to reach 50% complete mature midazolam and 1`-hydroxymidazolam metabolite/4`-hydroxymidazolam metabolite clearances was 1.0 and 0.97 years postmenstrual age. The final model suggested a decrease in midazolam clearance with increase in alanine transaminase and a lower clearance of the glucuronide metabolites with a renal dysfunction. In the pharmacogenomic analysis, rs62298861 and rs28365062 in the UGT2B7 gene were in high linkage disequilibrium. Minor alleles were associated with a higher 1`-hydroxymidazolam metabolite clearance in Caucasians. In the pharmacokinetic-pharmacogenomic model, clearance was expected to increase by 10% in heterozygous and 20% in homozygous for the minor allele with respect to homozygous for the major allele.
CONCLUSIONS: This work leveraged available knowledge on nonheritable and heritable factors affecting midazolam pharmacokinetic in pediatric subjects with primary respiratory failure requiring mechanical ventilation, providing the basis for a future implementation of an individual-based approach to sedation.
参考来源
- Zuppa AF, Conrado DJ, Zane NR, et al. Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study. Crit Care Med. 2019. PMID: 30672747. doi:10.1097/CCM.0000000000003638
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。